Advanced Search
Clinical Trials
Explore 601 FDA-approved clinical trials

CATEGORY


SEARCH FILTER

Recruitment Status
Study Type
Date of Registation
-


Region
Method of Allocation
Masking
Assignment
Phase


  
Results 81 - 90 of 601

Video-based education as an adjunct treatment for pediatric atopic dermatitis

Recruitment Status
Pending
Project Status
Ongoing
Project Description
Atopic dermatitis (AD) is a chronic, relapsing, inflammatory skin disease and is one of the most common skin disorders in children. This disease greatly affects the well-being and quality of life of the patients and their family members. Several researches emphasized the importance of edu . . .
Primary Sponsor
Rizal Medical Center Department of Dermatology
Study Type
Interventional
Date of Registration
24 August 2021
Date of FIrst Enrollment
30 November -0001
Region
NCR
Method of Allocation
Randomized
Masking
Single Blind
Assignment
Single
Phase
Phase I
Sources of Monetary or Material Support
Self-funded
Primary Outcomes

Effectiveness of video-based education as an adjunct treatment for atopic dermatitis

Key Inclusion and Exclusion Criteria
Inclusion Criteria Age between 2 months to 18 years Newly diagnosed or previously diagnosed patients who are in flare irrespective of the pharmacological treatment (topical/systemic/phototherapy or combination) they are receiving Have a cellular phone/tab . . .
Health Condition(s) or Problem(s) Studied

The main objective of this study is to evaluate the effectiveness of video-based education as an adjunct treatment for atopic dermatitis.

 Specifically, this study aims to:

  1. Determine if video-based education will improve the severity of the disease as measured by the Scoring Atopic Dermatitis (SCORAD) Index.
  2. Determine if video-based education will improve the quality of life of parents, family members or guardians of patients with atopic dermatitis as measured by the Dermatitis Family Impact (DFI) Questionnaire.
  3. Determine the usability and impact of videos on the education and motivation of patients with atopic dermatitis using a satisfaction survey.

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial of MW33 Injection to Evaluate the Efficacy and Safety in Patients with Mild or Moderate COVID-19

Recruitment Status
Recruiting
Project Status
Ongoing
Project Description

The study is designed as a multicenter, randomized, double-blind, placebo-controlled clinical trial to evaluate the clinical efficacy and safety of MW33 injection in patients with mild or moderate COVID-19, and to evaluate its pharmacokinetic profile and immunogenicity.

Primary Sponsor
Mabwell (Shanghai) Bioscience Co., Ltd.
Secondary Sponsor
PAREXEL Clinical Research (Philippines) Ltd. Corp.
Study Type
Interventional
Date of Registration
10 March 2021
Date of FIrst Enrollment
14 May 2021
Region
China
Method of Allocation
Randomized
Masking
Double Blind
Assignment
Not Applicable
Phase
Phase II
FDA Clinical Trial Reference (CTR) Number
2021-CT0590
Sources of Monetary or Material Support
Mabwell (Shanghai) Bioscience Co., Ltd.
Primary Outcomes
Primary efficacy endpoints:Time-weighted average change in SARS-CoV-2 viral load in nasopharyngeal swabs from baseline to Day 7. Safety evaluation:1) Changes in vital signs (pulse, respiration, blood pressure and body temperature) at different timepoints before and after dosin . . .
Key Inclusion and Exclusion Criteria
Inclusion Criteria1) Patients diagnosed with mild or moderate COVID-19 2) Has at least one COVID-19 symptom, e.g., fever, cough, shortness of breath, sore throat, headache, muscle ache, and other respiratory or gastrointestinal symptoms, and has the symptom for ≤ 5 days prior to ran . . .
Countries of Recruitment
China, Philippines
Health Condition(s) or Problem(s) Studied

COVID-19

An Adaptive, Randomized, Double-blinded, Placebo-controlled, Phase II/III Trial of Monoclonal Antibody SCTA01 Against SARS-CoV-2 in Patients With Severe COVID-19 Admitted to High Dependence or Intensive Care Unit (MASP3 Trial)

Recruitment Status
Terminated
Project Status
Terminated
Project Description
The study is a multicenter, adaptive, randomized, double-blinded, and placebo-controlled Phase II/III trial. It will be conducted globally. The study will evaluate the efficacy and safety of SCTA01 compared to placebo both given with BSC in participants with severe COVID-19. The subjects will be . . .
Primary Sponsor
SinoCelltech, Ltd.
Secondary Sponsor
PAREXEL Clinical Research (Philippines) Ltd. Corp.
Study Type
Interventional
Date of Registration
16 April 2021
Date of FIrst Enrollment
01 May 2021
Region
China
Method of Allocation
Randomized
Masking
Triple Blind
Assignment
Parallel
Phase
Phase II/III
FDA Clinical Trial Reference (CTR) Number
2021-CT0595
Sources of Monetary or Material Support
SinoCelltech, Ltd.
Primary Outcomes

All-cause mortality rate at D29 [ Time Frame: Day 29 ]

The mortality rates in placebo and treatment groups regardless of the cause of death.
Key Inclusion and Exclusion Criteria
Inclusion Criteria: Male and female of ≥18years at time of enrollment; Subject (or legally authorized representative [LAR]) is able and willing to provide written or verbal informed consent, which includes compliance with study requirements and restrictions listed in th . . .
Countries of Recruitment
France, Germany, India, Philippines, Portugal, Romania, Russia, Spain, Ukraine
Health Condition(s) or Problem(s) Studied

COVID-19

The Effect in the Acid-base status, Electrolyte levels and Anion-gap following Initial Fluid Resuscitation in Children with Septic Shock with Normal saline, Lactated Ringers and Acetated Isotonic Electrolyte Solution

Recruitment Status
Recruiting
Project Status
Ongoing
Project Description

Clinical Trial Type 2  NOT intended for marketing registration

This is an open label randomized controlled trial

Primary Sponsor
University of the Philippines - Philippine General Hospital, Department of Pediatrics, Division of Pediatric Emergency Medicine
Secondary Sponsor
None
Study Type
Interventional
Date of Registration
17 May 2021
Date of FIrst Enrollment
01 May 2021
Region
NCR
Method of Allocation
Randomized
Masking
Open Label
Assignment
Not Applicable
Phase
Not Applicable
FDA Clinical Trial Reference (CTR) Number
none
Sources of Monetary or Material Support
Self-funded
Primary Outcomes

The study aims to determine the effects in the acid-base status, electrolyte levels and anion-gap following initial fluid resuscitation in children with septic shock with Normal Saline, Lactated Ringers and Acetated Isotonic Electrolyte Solution.

Key Inclusion and Exclusion Criteria
impaired organ perfusion With signs of delayed peripheral perfusion Exclusion criteria would include:  Patient who received fluid resuscitation and was given with sodium bicarbonate correction from other centers and institution Patients w . . .
Countries of Recruitment
Philippines, Germany, India, Philippines, Portugal, Romania, Russia, Spain, Ukraine
Health Condition(s) or Problem(s) Studied

The study aims to determine the effects in the acid-base status, electrolyte levels and anion-gap following initial fluid resuscitation in children with septic shock with Normal Saline, Lactated Ringers and Acetated Isotonic Electrolyte Solution.

Safety and Efficacy of MLC901 (NeuroAid II) in Patients with Moderate Traumatic Brain Injury: A Randomized Double-Blind Placebo-Controlled Trial

Recruitment Status
Recruiting
Project Status
Ongoing
Project Description
This is a randomized double blind placebo-controlled trial comparing the outcomes of patients with moderate traumatic brain injury given MLC 901 vs placebo. 120 patients will be recruited within 7 days of injury, and the investigrational product will be given for 6 months and patients followed-up . . .
Primary Sponsor
University of the Philippines
Study Type
Interventional
Date of Registration
23 February 2022
Date of FIrst Enrollment
30 November -0001
Region
NCR
Method of Allocation
Randomized
Masking
Double Blind
Assignment
Single
Phase
Phase II/III
Sources of Monetary or Material Support
MOLEAC PTE. LTD.
Primary Outcomes

GOS-E at 6 months

Key Inclusion and Exclusion Criteria
Inclusion Criteria:  1. Age 18 to 65 yrs 2. Moderate TBI, defined as Glasgow Coma Scale (GCS) score of 9 to 12 after initial resuscitation. 3. Presenting at the study site within 7 days of injury 4. Participant or his/her legal representative is able to comply wit . . .
Health Condition(s) or Problem(s) Studied

Moderate Traumatic Brain Injury

Individualized nutritional planning as an adjunct treatment for psoriasis: A pilot study

Recruitment Status
Completed
Project Status
Ongoing
Project Description
Psoriasis is a chronic, inflammatory, and multisystemic disease, associated with arthritis, cardiovascular disease, metabolic syndrome, mental health and inflammatory bowel syndrome. Most of the associated diseases of psoriasis are also linked with lifestyle risk facto . . .
Primary Sponsor
Rizal Medical Center Department of Dermatology
Secondary Sponsor
NOT APPLICABLE
Study Type
Interventional
Date of Registration
09 September 2021
Date of FIrst Enrollment
30 November -0001
Region
NCR
Method of Allocation
Non-Randomized
Masking
N/A
Assignment
Not Applicable
Phase
Phase 0
Sources of Monetary or Material Support
Rizal Medical Center Department of Dermatology
Primary Outcomes

The percentage reduction of the Psoriasis area and severity index score from baseline to week 4, 8 and 12

Key Inclusion and Exclusion Criteria
The participating patients were recruited from the Outpatient and Teledermatology services of the Department of Dermatology, Rizal Medical Center.  Included in the study were new and old patients diagnosed with Psoriasis . . .
Countries of Recruitment
Philippines, Germany, India, Philippines, Portugal, Romania, Russia, Spain, Ukraine
Health Condition(s) or Problem(s) Studied

Psoriasis

A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Anifrolumab in Asian Participants with Active Systemic Lupus Erythematosus (AZALEA)

Recruitment Status
Recruiting
Project Status
Ongoing
Project Description
This is a Phase III, multicenter, multinational, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of an intravenous(IV) treatment regimen of 300 mg anifrolumab versus placebo in Asian participants with moderate to severe active, autoantibody positive systemic . . .
Primary Sponsor
AstraZeneca AB
Study Type
Interventional
Date of Registration
04 October 2021
Date of FIrst Enrollment
13 September 2021
Region
Sweden
Method of Allocation
Randomized
Masking
Double Blind
Assignment
Single
Phase
Phase II/III
FDA Clinical Trial Reference (CTR) Number
2021-CT0613
Sources of Monetary or Material Support
AstraZeneca AB
Primary Outcomes

To evaluate the effect of anifrolumab compared to placebo on disease activity as measured by the difference in the proportion of participants achieving BICLA response at Week 52

Key Inclusion and Exclusion Criteria
Inclusion criteriaParticipants are eligible to be included in the study only if all of the following criteria apply:Informed Consent1 Capable of giving signed informed consent as described in Appendix A which includes compliance . . .
Countries of Recruitment
China, Hong Kong, Philippines, South Korea, Taiwan, Thailand, Russia, Spain, Ukraine
Health Condition(s) or Problem(s) Studied

Active Systemic Lupus Erythematosus

A 96-week, two-arm, randomized, single-masked, multi-center, phase III study assessing the efficacy and safety of brolucizumab 6 mg compared to panretinal photocoagulation laser in patients with proliferative diabetic retinopathy (CONDOR)

Recruitment Status
Recruiting
Project Status
Ongoing
Project Description
The study is a 96-week, two-arm, randomized, single-masked, multi-center, active-controlled, non-inferiority study in patients with proliferative diabetic retinopathy (PDR). Subjects who meet all the inclusion and none of the exclusion criteria will be randomized in a 1:1 ratio to one of . . .
Primary Sponsor
Novartis Healthcare Philippines, Inc.
Study Type
Interventional
Date of Registration
16 February 2021
Date of FIrst Enrollment
15 April 2021
Region
NCR
Method of Allocation
Randomized
Masking
Single Blind
Assignment
Parallel
Phase
Phase III
FDA Clinical Trial Reference (CTR) Number
2020-CT0583
Sources of Monetary or Material Support
Novartis Pharma Services AG
Primary Outcomes
Primary objective(s) Endpoint(s) for primary objective(s) To demonstrate that brolucizumab is non-inferior to PRP with respect to the change from Baseline in visual . . .
Key Inclusion and Exclusion Criteria
Key Inclusion criteria ·       Signed informed consent must be obtained prior to participation in the study. ·       Patients ≥ 18 years of age at Screening. ·       Participant cooperation suff . . .
Countries of Recruitment
Argentina, Australia, Brazil, Canada, Chile, China, India, Japan, Mexico, Philippines, Russia, Saudi Arabia, South Korea, Taiwan, Turkey, United States
Health Condition(s) or Problem(s) Studied

Proliferative Diabetic Retinopathy

A Multi-center, Randomized, Double-blind, Placebo-controlled Phase II/III Clinical Trial to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 Inactivated (Vero Cell) Vaccine in the Elderly 60-80 Years of Age, Coronovac ENCOV19 Study

Recruitment Status
Pending
Project Status
Ongoing
Project Description
This is a randomized, double-blind, phase II/III study to evaluate the safety, and immunogenicity of an investigational inactivated SARS-CoV-2 vaccine, in volunteers aged 60 to 80 years. A total of 352 subjects will be . . .
Primary Sponsor
IP Biotech, Inc.
Study Type
Interventional
Date of Registration
11 February 2021
Date of FIrst Enrollment
06 April 2021
Region
NCR
Method of Allocation
Randomized
Masking
Double Blind
Assignment
Parallel
Phase
Phase II/III
FDA Clinical Trial Reference (CTR) Number
2020-CT0570
Sources of Monetary or Material Support
IP Biotech, Inc.
Primary Outcomes
  1. To evaluate the safety of SARS-CoV-2 inactivated (Vero Cell) vaccine; and

  2. To evaluate the immunogenicity of a two dose regimen of SARS-CoV-2 inactivated (Vero Cell) vaccine.

Key Inclusion and Exclusion Criteria
Inclusion Criteria: Ability to provide written informed consent and availability to fulfill the study requirements. Elderly, 60-80 years of age, male or female. . . .
Countries of Recruitment
Philippines, Australia, Brazil, Canada, Chile, China, India, Japan, Mexico, Philippines, Russia, Saudi Arabia, South Korea, Taiwan, Turkey, United States
Health Condition(s) or Problem(s) Studied

COVID 19 Vaccine

A Phase III double-blind study to assess safety and
efficacy of an RSV Maternal unadjuvanted vaccine,
in pregnant women and infants born to vaccinated
mothers

Recruitment Status
Pending
Project Status
Ongoing
Project Description
GSK is developing an investigational Respiratory Syncytial Virus (RSV) vaccine foradministration to pregnant women, with the aim of preventing medically assessed, RSV-associatedlower respiratory tract illnesses (LRTIs) in their infants by transfer of maternalantibodies. The vacc . . .
Primary Sponsor
GlaxoSmithKline Philippines, Inc.
Study Type
Interventional
Date of Registration
15 February 2021
Date of FIrst Enrollment
05 April 2021
Region
NCR
Method of Allocation
Randomized
Masking
Double Blind
Assignment
Single
Phase
Phase III
FDA Clinical Trial Reference (CTR) Number
2020-CT0584
Sources of Monetary or Material Support
GlaxoSmithKline Biologicals
Primary Outcomes
From birth (Visit 1-NB) to 6 months (Visit 4-NB), occurrencesof medically assessed, RSV-associated severe (includingvery severe) LRTIs according to the case definitions. or From birth (Visit 1-NB) to 6 months (Visit 4-NB), occurrencesof any medically assessed, RS . . .
Key Inclusion and Exclusion Criteria
Maternal participants must satisfy all the following criteria at study entry:• Participants who, in the opinion of the investigator, can and will comply with therequirements of the protocol (e.g. completion of diaries, return for follow-up visits).• Participants who give wri . . .
Countries of Recruitment
Argentina, Australia, Bangladesh, Belgium, Brazil, Canada, Colombia, Finland, France, India, Italy, Mexico, New Zealand, Panama, Philippines, Russia, South Africa, South Korea, Spain, Taiwan, Thailand, United Kingdom, United States
Health Condition(s) or Problem(s) Studied

Respiratory Syncytial Virus (RSV)-associated Lower Respiratory Tract Illness (LRTI)

Results 81 - 90 of 601
Loading…
©2022 HERDIN PLUS. All rights reserved. | Contact Us | Keep up to date